Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry-Reference-Cited by-同舟云学术

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry

Published:2018-01-25 Issue:1 Volume:18 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Jo Helen E.^ORCID,Glaspole Ian,Moodley Yuben,Chapman Sally,Ellis Samantha,Goh Nicole,Hopkins Peter,Keir Greg,Mahar Annabelle,Cooper Wendy,Reynolds Paul,Haydn Walters E.,Zappala Christopher,Grainge Christopher,Allan Heather,Macansh Sacha,Corte Tamera J.

Funder

National Health and Medical research Council

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-018-0575-y.pdf

Reference21 articles.

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

2. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806.

3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.